Pacira BioSciences, Inc.
PCRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$36.42
KIRA · Stoqly’s AI analyst, in plain words
- Pacira BioSciences, Inc. had $726M of revenue in fiscal 2025, up 3.6% on the year before. Over five years, revenue changed +11.1% a year on average.
- Its operating margin was 2.6%, up 13.1 pts: of every 100 in sales, about 3 is left after running the business.
- Pacira BioSciences, Inc. made $7.0M of net profit in fiscal 2025.
- Free cash flow was $137M in fiscal 2025, 18.8% of revenue.
- Pacira BioSciences, Inc. returned $148M to shareholders in fiscal 2025, 109% of free cash flow. The diluted share count fell 2.6%.
- Pacira BioSciences, Inc. owes $134M more than it holds in cash, about 1.2 years of operating profit.
Market cap
$1.5B
P/E
101.2x
Revenue
$726M
Net income
$7.0M
Free cash flow
$137M
Operating margin
2.6%
Pacira BioSciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+3.6%
Only a little. Sales grew 3.6% last year.
Does it make a profit?
1.0%
A little. It keeps 1.0% of every sale as profit.
Does profit turn into cash?
18.8%
Yes. 18.8% of sales ends up as free cash.
Is debt under control?
1.2x
Keep an eye on it. Repaying its debt would take 1.2 years of operating profit.
How healthy are the accounts?
9 / 9
Solid. It passes 9 of 9 health tests.
How is the share priced?
101.2x
One share costs 101.2 times its yearly profit per share.
What Pacira BioSciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Pacira BioSciences, Inc.
- CIK
- 0001396814
Pacira BioSciences, Inc. · PCRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $542M | $667M | $675M | $701M | $726M |
| Revenue growth | 26.0% | 23.1% | 1.2% | 3.9% | 3.6% |
| Gross margin | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| Operating margin | 16.6% | 9.0% | 13.0% | −10.5% | 2.6% |
| Net income | $42.0M | $15.9M | $42.0M | −$99.6M | $7.0M |
| Net margin | 7.8% | 2.4% | 6.2% | −14.2% | 1.0% |
| Diluted EPS | $0.92 | $0.34 | $0.89 | −$2.15 | $0.16 |
| Cash | |||||
| Cash from operations | $126M | $145M | $155M | $189M | $152M |
| Capital expenditure | $45.9M | $30.1M | $15.2M | $10.6M | $15.3M |
| Free cash flow | $79.9M | $115M | $139M | $179M | $137M |
| FCF margin | 14.7% | 17.3% | 20.7% | 25.5% | 18.8% |
| Share buybacks | — | $0.0M | $0.0M | $25.0M | $148M |
| Share count change | 4.5% | 2.0% | 11.7% | −11.0% | −2.6% |
| Debt and strength | |||||
| Cash and short-term investments | $656M | $289M | $279M | $485M | $238M |
| Debt incl. finance leases | — | $689M | $522M | $787M | $372M |
| Shareholders' equity | $730M | $775M | $870M | $778M | $693M |
| Net debt / EBITDA | — | 2.6x | 1.5x | 55.9x | 1.2x |
| Current ratio | 1.7x | 3.4x | 5.2x | 2.4x | 4.5x |
| Interest coverage | 2.8x | 1.5x | 4.3x | −4.4x | 1.1x |
| Returns and quality | |||||
| Return on capital | — | 5.1% | 5.4% | −5.4% | 1.5% |
| Return on equity | 6.2% | 2.1% | 5.1% | −12.1% | 1.0% |
| Return on tangible equity | — | 22.3% | 18.8% | −28.3% | 2.3% |
| Piotroski F-score | 4 | 5 | 8 | 5 | 9 |
| Altman Z'' | 1.6 | 2.2 | 3.2 | 2.1 | 3.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.8M
5 insiders
Of sales under plans
100%
$2.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pacira BioSciences, Inc. · PCRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $36.42 a share, the company is worth $1.5B: 101.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001396814). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.